top of page

Oncology expert Paul Rennert gives an update on Aleta Biotherapeutics and previews some targets at #ASCO24

Paul Rennert talks about the first four patients who have been dosed in Aleta's clinical trial, as well as previewing targets such as Claudin 18.2 and BCMA at ASCO.



Comments


Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

bp-logo.png

Breakthrough Properties is a life science real estate company that is exclusively focused on delivering cutting-edge environments for the life science industry. With a portfolio of roughly 5 million square feet across the US, UK and continental Europe, Breakthrough has emerged as a leading partner for high-growth biotechs and pharmas around the world. 

bottom of page